,,,well,,,, our team has had 21 years in research and failed every trial,,,,,if it wasn't for ad hoc analysis or evaluations of our science by third parties,,,we would have been sidelined years ago....its stunning how ZEN seems to be able to advance trials even during C19 issues while the other company cant seem to wipe it's back side!!!,,,,it would be logical to assume the progression here is due to knoweldge and understanding of how research advancement works in an FDA setting and having weight of BP with you. ,,Maybe the other company should partner up,,,,novel idea,,,,our shares might break out of the mid forty cent range,,,,jmo